Table 2.
Operative outcomes for patients undergoing PED or TET approaches.
| Unmatched cohort | p-value | Matched cohort | p-value | |||
|---|---|---|---|---|---|---|
| PED (n = 37) | TET (n = 172) | PED (n = 37) | TET (n = 37) | |||
| Last angiographic follow-up | 36 (97.4%) | 132 (76.7%) | 0.004* | 36 (97.4%) | 26 (70.3%) | 0.002* |
| Follow-up in months, median (IQR) | 12.0 (6.0–12.0) | 8.0 (6.0–15.0) | 0.692 | 12.0 (6.0–12.0) | 8.0 (6.0–28.0) | 0.586 |
| Occlusion status in last follow-up | - | |||||
| Completely occluded | 33 (91.7%) | 125 (94.7%) | 0.777 | 33 (91.7%) | 24 (92.3%) | 1 |
| Near completely occluded with neck remnant | 3 (8.3%) | 5 (3.8%) | 0.488 | 3 (8.3%) | 1 (3.8%) | 0.853 |
| Incompletely occluded | 0 (0%) | 2 (1.5%) | 1 | 0 | 1 (3.8%) | 0.419 |
| Treatment-related complications | 5 (13.5%) | 20 (11.6%) | 0.967 | 5 (13.5%) | 5 (13.5%) | 1 |
| Clinical follow-up | - | - | ||||
| Good (mRS = 0–2) | 35 (94.6%) | 167 (97.1%) | 0.306 | 35 (94.6%) | 36 (97.3%) | 0.607 |
| Poor (mRS = 3–5) | 2 (5.4%) | 5 (2.9%) | 0.793 | 2 (5.4%) | 1 (2.7%) | 1 |
| Death (mRS = 6) | 0 (0%) | 0 (0%) | 1 | 0 (0%) | 0 (0%) | 1 |
Data are reported for the overall series and the propensity score-matched groups. PED, pipeline embolization device; TET, traditional endovascular therapeutic; *, significant result; IQR, interquartile range; mRS, modified Rankin Scale.